Global Trade Alert
Global Trade Alert

United States of America: U.S. Administration issues Executive Order to implement Most-Favoured-Nation prescription drug pricing

Announcement

12 May 2025

In May 2025, the US Administration issued an Executive Order directing federal agencies to ensure that American patients pay no more than the lowest price charged for prescription drugs in other developed nations.

Source

Sign in to access

Number of interventions

1

0 certainly harmful

1 likely harmful

0 liberalising

List of interventions

Implementation date

No implementation date

Revocation date:

No revocation date

Updated: 11 Nov 2025
Instrument unclear
On 12 May 2025, the U.S. Administration issued an Executive Order titled “Delivering Most-Favoured-Nation (MFN) Prescription Drug Pricing to American Patients.” The order directs the Department of Hea...
Sign in to see more

Related State Acts

23 Apr 2026

United States of America: Agreement with Regeneron on Most-Favoured-Nation drug pricing and tariff exemption

12 Jan 2026

United States of America: Agreement with AbbVie on Most-Favoured-Nation drug pricing and tariff exemption

08 Jan 2026

United States of America: Agreement with Johnson & Johnson on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Gilead on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with GSK on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Merck on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Novartis on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Sanofi on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Amgen on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Boehringer Ingelheim on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Bristol Myers Squibb on Most-Favoured-Nation drug pricing and tariff exemption

19 Dec 2025

United States of America: Agreement with Genentech on Most-Favoured-Nation drug pricing and tariff exemption

01 Apr 2025

United States of America: U.S. Administration imposes Section 232 tariffs on pharmaceutical imports

Threads

See all

This state act is not part of any Thread yet.